Bionano’s Optical Genome Mapping Reveals New Insights and Prognostic Capabilities Compared to Traditional Cytogenetics Techniques in Several Leukemia Clinical Research Studies Presented at the ECA

SAN DIEGO, July 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced optical genome mapping (OGM) reveals new insights and prognostic capabilities compared to traditional cytogenetics techniques in several leukemia clinical research studies presented at the 2021 European Cytogenomics Conference (ECA).